Companies

Torrent Pharma joins hands with Glenmark to co-market diabetes drug

Our Bureau New Delhi | Updated on July 11, 2019 Published on July 11, 2019

About two months after launching novel anti-diabetic drug Remogliflozin etabonate (Remogliflozin) in India, global drug firm Glenmark Pharmaceuticals Ltd on Thursday inked an agreement with Indian pharma major Torrent Pharmaceuticals Limited to co-market the drug in the country.

In a joint statement, Torrent and Glenmark said that they have entered into a non-exclusive sub-licensing agreement to co-market sodium glucose co-transporter-2 (SGLT2) inhibitor Remogliflozin Etabonate in India.

Under the terms of the agreement, Glenmark will receive an upfront payment, license fees and royalties for the non-exclusive sub-license rights from Torrent.

Glenmark will manufacture and supply Remogliflozin while Torrent will market the drug under its own trademark ‘Zucator’ brand in India.

Remogliflozin is an innovative, patent-protected SGLT2 inhibitor indicated in treatment of Type-2 Diabetes Mellitus in adults.

SGLT2 inhibitors are cutting-edge, globally-accepted latest class of oral anti-diabetes drugs that provide glycemic control, induce weight loss and reduce cardiovascular risks.

In April, Glenmark had become the first-ever company to launch Remogliflozin, thereby making India the first country to get access to the drug.

The Drugs Controller General of India (DCGI) had granted an approval to Glenmark for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials in which Remogliflozin demonstrated good efficacy and safety profile in a head-to-head comparison against Dapagliflozin.

Remogliflozin is the only SGLT2 inhibitor to be manufactured in India from active pharmaceutical ingredient (API) to formulation.

“The burden of diabetes in India is growing at an alarming rate and through this collaboration, we aim to improve access to the latest, novel and globally-researched SGLT2 inhibitor by providing an effective, high quality and world-class treatment option to patients in India,” said Sujesh Vasudevan, President, India Formulations, Middle East and Africa, Glenmark Pharmaceuticals.

“This partnership will also lay the foundation for a long-term collaboration with Torrent for Remogliflozin in terms of its additional line extensions and further clinical development,” Vasudevan added..

Dhruv Gulati, Executive Director (India & ROW), Torrent Pharma, said: “The drug will augment the Type-2 Diabetes Mellitus treatment armamentarium in the country and this partnership will be an important step towards enhancing access to the growing needs of diabetic patients."

Published on July 11, 2019

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.